UCB Gestione

Gestione criteri di controllo 3/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Jean-Christophe Tellier

Amministratore delegato

€6.7m

Compenso totale

Percentuale dello stipendio del CEO	19.4%
Mandato del CEO	9.9yrs
Proprietà del CEO	n/a
Durata media del management	5yrs
Durata media del Consiglio di amministrazione	10.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Jean-Christophe Tellier rispetto agli utili di UCB?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2024	n/a	n/a	€240m
Mar 31 2024	n/a	n/a	€292m
Dec 31 2023	€7m	€1m	€343m
Jun 30 2023	n/a	n/a	€332m
Mar 31 2023	n/a	n/a	€376m
Dec 31 2022	€6m	€1m	€420m
Jun 30 2022	n/a	n/a	€887m
Mar 31 2022	n/a	n/a	€971m
Dec 31 2021	€6m	€1m	€1b
Sep 30 2021	n/a	n/a	€996m
Jun 30 2021	n/a	n/a	€936m
Mar 31 2021	n/a	n/a	€834m
Dec 31 2020	€7m	€1m	€732m
Jun 30 2020	n/a	n/a	€743m
Mar 31 2020	n/a	n/a	€767m
Dec 31 2019	€87k	n/a	€790m
Jun 30 2019	n/a	n/a	€652m
Mar 31 2019	n/a	n/a	€722m
Dec 31 2018	n/a	n/a	€792m
Jun 30 2018	n/a	n/a	€872m
Mar 31 2018	n/a	n/a	€812m
Dec 31 2017	€76k	n/a	€752m

Compensazione vs Mercato: La retribuzione totale di Jean-Christophe ($USD 6.95M ) è superiore alla media delle aziende di dimensioni simili nel mercato Austrian ($USD 4.36M ).

Compensazione vs guadagni: La retribuzione di Jean-Christophe è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Jean-Christophe Tellier (65 yo)

9.9yrs

Mandato

€6,662,655

Compensazione

Dr. Jean-Christophe Tellier serves as Executive Vice President and President of European Operations at Ucb S.A. Dr. Tellier served as President and General manager of North American operations at Ipsen S.A...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Jean-Christophe Tellier	CEO & Executive Director	9.9yrs	€6.66m	Nessun dato
Sandrine Dufour	Executive VP	4.4yrs	Nessun dato	Nessun dato
Kirsten Lund-Jurgensen	Executive Vice President of Supply & Technology Solutions	5.3yrs	Nessun dato	Nessun dato
Denelle J. Johnson	Executive VP & General Counsel	1.7yrs	Nessun dato	Nessun dato
Jean-Luc Fleurial	Executive VP & Chief Human Resources Officer	4.8yrs	Nessun dato	Nessun dato
Emmanuel Caeymaex	Executive VP & Chief Commercial Officer	9.8yrs	Nessun dato	Nessun dato
Fiona du Monceau	Executive Vice President of Patient Evidence	less than a year	€164.00k	Nessun dato
Caroline Vancoillie	Chief Accounting Officer	11.8yrs	Nessun dato	Nessun dato
Alistair Henry	Executive VP & Chief Scientific Officer	less than a year	Nessun dato	Nessun dato
Antje Witte	Head of Investor Relations	14.9yrs	Nessun dato	Nessun dato
Gwendoline Ornigg	Head of Global Communication	no data	Nessun dato	Nessun dato
Veronique Toully	Head of Sustainability	no data	Nessun dato	Nessun dato

5.0yrs

Durata media

57.5yo

Età media

Gestione esperta: Il team dirigenziale di UCB è esperto e expertise (durata media dell'incarico 5 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Jean-Christophe Tellier	CEO & Executive Director	10.7yrs	€6.66m	Nessun dato
Gerhard Mayr	Honorary Chairman	no data	€70.00k	Nessun dato
Mark Eyskens	Honorary Chairman	19.9yrs	€15.50k	Nessun dato
Daniel Janssen	Honorary Deputy Chairman	no data	€28.50k	Nessun dato
Georges Jacobs Hagen	Honorary Chairman	no data	€30.00k	Nessun dato
Diégo du de Bergendal	Honorary Chairman	3.7yrs	€87.50k	Nessun dato
Karel Boone	Honorary Chairman	no data	€49.00k	Nessun dato
Dame Davies	Independent Director	10.7yrs	€138.00k	Nessun dato
Jonathan Peacock	Independent Chair of the Board	3.7yrs	€341.83k	Nessun dato
Charles-Antoine Emmanuel Janssen	Vice-Chair of the Board	12.7yrs	€108.50k	Nessun dato
Jonkheer van Rijckevorsel	Director	10.7yrs	€86.00k	Nessun dato
Rodolfo Savitzky	Independent Director	less than a year	Nessun dato	Nessun dato

10.7yrs

Durata media

73yo

Età media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di UCB è composto da personale esperto e esperto (durata media dell'incarico 10.7 anni).

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2024/12/23 08:40
Prezzo dell'azione a fine giornata	2024/12/20 00:00
Guadagni	2024/06/30
Guadagni annuali	2023/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

^* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .

Fonti analitiche

UCB SA è coperta da 48 analisti. 16 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Mark van der Geest	ABN AMRO Bank N.V.
Kamla Singh	AlphaValue
Brian Bourdot	Barclays

UCB Gestione

Gestione criteri di controllo 3/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

UCB SA, Annual General Meeting, Apr 24, 2025

Insufficient new directors

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

UCB SA, Annual General Meeting, Apr 27, 2023

UCB SA, Annual General Meeting, Apr 28, 2022

UCB Announces Changes on Board of Directors

Recent updates

UCB SA Receives U.S. FDA Approval for Bimzelx (Bimekizumab-Bkzx) as the First Il-17A and Il-17F Inhibitor for Adults with Moderate-Severe Hidradenitis Suppurativa

Ucb Announces New Bimzelx (Bimekizumab-Bkzx) Data at Acr Convergence 2024

UCB Announces Head-To-Head Study Evaluating Bimekizumab (bimekizumab) versus SKYRIZI® (risankizumab) in Active Psoriatic Arthritis

UCB Announces Late-Breaking Two-Year Data for BIMZELX (bimekizumab-bkzx) in Moderate-to-Severe Hidradenitis Suppurativa at EADV 2024

New minor risk - Profit margin trend

First half 2024 earnings released: EPS: €1.10 (vs €1.64 in 1H 2023)

UCB Announces New CIMZIA® Data for Women Living with Chronic Rheumatic Diseases Throughout Pregnancy, and for People Living with Ra and High Rheumatoid Factor Levels

UCB SA, Annual General Meeting, Apr 24, 2025

Insufficient new directors

UCB SA to Report First Half, 2024 Results on Jul 25, 2024

UCB Announces FDA Accepts Supplemental Biologics License Applications for Bimzelx

UCB Announces 48-Week Phase 3 Analyses of Pooled Phase 3 Data from the BE HEARD I and BE HEARD II Studies

Full year 2023 earnings released: EPS: €1.81 (vs €2.22 in FY 2022)

UCB Presents New Data About the Real-World Experience of FINTEPLA® (Fenfluramine) and Rare Epilepsy Syndromes At 2023 American Epilepsy Society (AES) Annual Meeting

UCB SA Announces U.S. Availability of BIMZELX for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB to Present Post Hoc Analysis of the EXXELERATE Trial Evaluating the Efficacy of CIMZIA®? (Certolizumab Pegol) and Adalimumab in Patients with Rheumatoid Arthritis and High Rheumatoid Factor

UCB Presents Latest Data from Generalized Myasthenia Gravis Portfolio

UCB SA Announces Publication of NAYZILAM® (midazolam) Results in 'Epilepsy & Behavior' Examining the Impact of Dose on Return to Full Baseline Function (RTFBF) for People with Seizure Clusters

UCB Announces U.S. FDA Approves BIMZELX (Bimekizumab-Bkzx) for the Treatment of Adults with Moderate-To-Severe Plaque Psoriasis

UCB Announces U.S. FDA approval of ZILBRYSQ® (zilucoplan) for the Treatment of Adults with Generalized Myasthenia Gravis

UCB Reinforces Commitment to Advancing Care in Hidradenitis Suppurativa with Six Abstracts at SHSA 2023

UCB Announces Phase 3 Data Analysis Presented at EADV 2023 Showed Bimekizumab Achieved High Thresholds of Clinical Response in Hidradenitis Suppurativa

UCB SA to Report Fiscal Year 2023 Results on Feb 21, 2024

First half 2023 earnings released: EPS: €1.64 (vs €2.10 in 1H 2022)

Ucb Announces That Rystiggo Is Commercially Available for the Treatment of Adult Patients in the U.S. with Generalized Myasthenia Gravis (Gmg) Who Are Anti-Acetylcholine Receptor (Achr) or Anti-Muscle-Specific Tyrosine Kinase (Musk) Antibody Positive

UCB Announces Resignation of Head of Neurology Solutions Charl Van Zyl

Upcoming dividend of €0.93 per share at 1.5% yield

Full year 2022 earnings released: EPS: €2.22 (vs €5.58 in FY 2021)

UCB Announces Annals of the Rheumatic Diseases Publishes Results from Two Bimekizumab Phase 3 Studies in Axial Spondyloarthritis

UCB SA to Report Fiscal Year 2022 Results on Feb 22, 2023

UCB Announces Rozanolixizumab BLA for the Treatment of Generalized Myasthenia Gravis Filed with U.S. FDA and Designated for Priority Review

UCB Announces Positive Phase 3 Studies for Bimekizumab in Hidradenitis Suppurativa

UCB SA to Present Data At the American Epilepsy Society 76Th Annual Meeting 2022 Supporting A Decades-Long Commitment to Transforming Epilepsy Care

UCB Announces the Publication of Long-Term Open-Label Extension (OLE) Study Results of FINTEPLA® (Fenfluramine) CIV in Epilepsia

UCB Announces U.S. FDA Acceptance of New Drug Application and EMA MAA Validation for Zilucoplan for the Treatment of Generalized Myasthenia Gravis in Adult Patients

UCB Announces the First Presentation of Long-Term, 52-Week Data from Three Phase 3 Studies Evaluating the Efficacy and Safety of Bimekizumab in Adults with Active Psoriatic Arthritis

UCB Announces New Three-Year Results from the BE BRIGHT Open-Label Extension Study

First half 2022 earnings released

UCB, Announces New 24-Week Data from Two Phase 3 Studies, Be Mobile 1 and Be Mobile 2

UCB SA Announces First Detailed Data from Two Phase 3 Bimekizumab Studies in Psoriatic Arthritis to Be Presented At EULAR 2022

UCB SA, Annual General Meeting, Apr 27, 2023

UCB Presents Efficacy and Safety Results for Zilucoplan and Rozanolixizumab in Generalized Myasthenia Gravis

UCB Announces Jama Neurology Publishes Phase 3 Study Results on the Efficacy and Safety of Fintepla® (Fenfluramine) Oral Solution in Lennox-Gastaut Syndrome

UCB SA Announces Oral Solution Civ Approves for Treatment of Seizures Associated with Lennox-Gastaut Syndrome

UCB SA, Annual General Meeting, Apr 28, 2022

UCB Announces Positive Data in Myasthenia Gravis with Zilucoplan Phase 3 Study Results

UCB Announces Positive Top-Line Results for bimekizumab in Second Phase 3 Psoriatic Arthritis Study

UCB SA Announces Positive Top-Line Interim Analysis Results Showing That the Phase 3 Be Mobile 1 Study Met the Primary and All Ranked Secondary Endpoints

UCB SA Announces Positive Top-Line Interim Analysis Results from the Phase 3 Be Mobile 2 Study

UCB Announces Positive Phase 3 Results for Rozanolixizumab in Generalized Myasthenia Gravis

First half 2021 earnings released: EPS €3.00 (vs €1.92 in 1H 2020)

UCB Announces New Data from Rheumatology Portfolio Demonstrates Real World Value for Patients with axSpA, PsA, and Women of Childbearing Age

Independent Vice Chairman Pierre Gurdjian has left the company

Chairman Diégo du de Bergendal has left the company

Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs

Full year 2020 earnings released: EPS €3.87 (vs €4.22 in FY 2019)

New 90-day low: €83.86

UCB Announces Changes on Board of Directors

New 90-day low: €84.30

UCB SA to Report First Half, 2021 Results on Jul 29, 2021

doc.ai and UCB Teams Up to Develop Breakthrough Artificial Intelligence Models to Advance Care

UCB and Stanford Medicine Establish Multi-Year Collaboration

UCB Announces U.S. Food and Drug Administration Approval of VIMPAT

UCB SA (ENXTBR:UCB) agreed to acquire Handl Therapeutics from Gemma Frisius Fonds NV.

UCB Announces New Data on Its TNF Inhibitor

Bimekizumab Phase 3 Data Shows Superior Skin Clearance over Humira® in Moderate-To-Severe Psoriasis Patients

New 90-day low: €84.98

New 90-day low: €94.86

UCB Announces That the FDA and EMA Have Accepted the Biologics License Application (BLA) and Marketing Authorization Application (MAA), Respectively, for Bimekizumab for the Treatment of Adults with Moderate to Severe Plaque Psoriasis